Search
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigationalArtesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: AS, butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] esterZomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983. … Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.
Categories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesSynonyms: 5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acidLedipasvir
go.drugbank.com/drugs/DB09027ApprovedApproved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [ribavirin] depending on the level of liver damage or cirrhosis [FDA Label]. … Ledipasvir and other direct acting antivirals are very potent options for the treatment of Hepatitis C, as they exhibit a high barrier to the development of resistance [A19593].
Mixtures: HARVONI®Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalOriginally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … in the context of resistant cancers.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersNorelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin is a progestin used as the progestational component of combined hormonal contraceptives. … Norelgestromin was first approved in the United States in 2001 as the progestin in a norelgestromin and ethinyl estradiol transdermal contraceptive system.[L63816]
Mixtures: EVRA®, Evra -(6/0.75)Categories: Sex Hormones and Modulators of the Genital System, Cytochrome P-450 SubstratesVancomycin
go.drugbank.com/drugs/DB00512ApprovedInvestigationalIt is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. … As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexProducts: VANCOMICINA BONISCONTRO E GAZZONE, İNFÜZYONLUK VE ORAL ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ, 1 ADETAlbumin Aggregated
go.drugbank.com/drugs/DB14230ApprovedAlbumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote … of a SERD represents a therapeutic approach for the treatment of endocrine-resistant breast cancers.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-olHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.
Mixtures: Ser-Ap-Es, Ser-AP-ES TabCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 CYP3A Inhibitors